Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Operating Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Operating Expenses for 6 consecutive years, with $12.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 119.11% to $12.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $51.1 million, a 154.82% increase, with the full-year FY2024 number at $28.6 million, up 40.48% from a year prior.
  • Operating Expenses was $12.8 million for Q3 2025 at Inhibikase Therapeutics, up from $10.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $14.6 million in Q1 2025 to a low of $4.0 million in Q2 2021.
  • A 5-year average of $6.5 million and a median of $4.8 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 584.28% in 2021, then decreased 20.07% in 2024.
  • Inhibikase Therapeutics' Operating Expenses stood at $5.0 million in 2021, then dropped by 12.79% to $4.4 million in 2022, then grew by 0.11% to $4.4 million in 2023, then skyrocketed by 193.6% to $12.9 million in 2024, then decreased by 1.24% to $12.8 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Operating Expenses are $12.8 million (Q3 2025), $10.8 million (Q2 2025), and $14.6 million (Q1 2025).